RAD52 and cancer: Although identification of DNA repair factors involved in each RAD52-mediated DNA repair pathway is required to reveal the mechanistic basis of the synthetic lethality of HR-deficient cancers with RAD52 inhibition, our results demonstrated that the RPA:RAD52 PPI is highly likely to be essential for RAD52 addiction in BRCA-deficient cancers.